An unusual case of donor-derived myelodysplastic syndrome following double-unit umbilical cord blood transplantation in acute lymphoblastic leukemia.
Umbilical cord-blood transplantation is considered an effective treatment strategy for acute lymphoblastic leukemia (ALL) when a human leukocyte antigen (HLA)-matched donor is unavailable. The use of a second unit helps ensure engraftment in larger adults and those with comorbidities, even though only one unit engrafts in most patients. Herein, we present the clinical and laboratory characteristics of a patient who developed donor-derived myelodysplastic syndrome (ddMDS) after double umbilical cord-blood transplantation (dUCB HSCT). To our knowledge, no cases of ddMDS have been described in a patient with a history of ALL in molecular remission after receiving a dUCB HSCT. Current molecular techniques, including analysis of short tandem repeats (STR) and fluorescence in situ hybridization (FISH) allowed us to firmly establish donor origin.
Division of Hematology-Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.
Ryan
R
Cotter
Vesna
V
Najfeld
Luis
L
Isola
Gustavo
G
Del Toro
Elizabeth
E
Roman
Bruce
B
Petersen
John
J
Mascarenhas
D000328:Adult; D001782:Blood Donors; D002869:Chromosome Aberrations; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects*; D005312:Fetal Blood / Q000166:cytology; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D008297:Male; D009190:Myelodysplastic Syndromes / Q000209:etiology* / Q000235:genetics; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000628:therapy*; D020080:Tandem Repeat Sequences